A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma based on a Phase III Trial of CHOP-Rituximab vs CHOP + (131)Iodine-Tositumomab

PURPOSE: There is currently no consensus on optimal front-line therapy for patients with follicular lymphomas (FL). We analyzed a Phase III randomized intergroup trial comparing 6 cycles of CHOP-R with six cycles of CHOP followed by iodine I-131 tositumomab radioimmunotherapy (RIT) to assess whether...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Press, Oliver W., Unger, Joseph M., Rimsza, Lisa M., Friedberg, Jonathan W., LeBlanc, Michael, Czuczman, Myron S., Kaminski, Mark, Braziel, Rita M., Spier, Catherine, Gopal, Ajay K., Maloney, David G., Cheson, Bruce D., Dakhil, Shaker R., Miller, Thomas P., Fisher, Richard I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3872052/
https://ncbi.nlm.nih.gov/pubmed/24130072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1120
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados